Search Results 531-540 of 16366 for anti-TNF drugs

1. Clinical trials - Oncology (Medical)

   Drugs used in chemotherapy, such as carboplatin ... The purpose of this study is to determine the preliminary anti-tumor activity and confirm the safety of VV1 in ...

2. Clinical trials - Oncology (Medical)

   Drugs used in chemotherapy, such as carboplatin ... Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL ...

3. A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria - Mayo Clinic

   (e.g., infliximab, adalimumab), and eosinophil-depleting drugs (e.g., benralizumab, pramipexole); (ii) routine (daily or every other day during 5 or more ...

4. Mayo Clinic: Preclinical Tests May Lead to New Approach to Treat CNS Lymphoma

   ... anti-cancer drugs do not do," says Han Tun, M.D., an oncologist at Mayo Clinic in Florida. "The drug has excellent brain penetration, which is a requirement ...

5. Pharmacokinetics and Pharmacodynamic Biomarkers of Janus Kinase Inhibitor Therapy in Patients with Ulcerative Colitis (PROPHETIC Study) - Mayo Clinic

   Pharmacokinetics and Pharmacodynamic Biomarkers of Janus Kinase Inhibitor Therapy in Patients with Ulcerative Colitis (PROPHETIC Study) · Overview · Participation ...

6. Immune checkpoint-induced hypoparathyroidism: A case from the endocrine teaching clinics

   Immune checkpoint inhibitor (ICI) drugs have revolutionized cancer therapy ... He started a combination immunotherapy of ipilimumab (anti-CTLA-4) and nivolumab ( ...

7. PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination with Anti-PD-1/L1 in Patients with Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Prophylactic anti-microbial therapy according to institutional protocols is acceptable. ... Patients who are on treatment with drugs known to prolong the ...

8. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers - Mayo Clinic

   methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to randomization. - Patients who have received acute, low ...

9. A Study to Evaluate the Effectiveness and Safety of Glepaglutide in the Treatment of Short Bowel Syndrome - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo Clinic ... Unstable biological therapy (e.g., anti-TNF-α, natalizumab, etc.) within 6 ...

10. Encorafenib (oral route) - Side effects & dosage - Mayo Clinic

    ... drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the ...